Trial Profile
Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2020
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 01 Mar 2019 Status changed from active, no longer recruiting to completed.
- 14 Feb 2019 Planned End Date changed from 28 Feb 2019 to 1 Jul 2019.
- 14 Feb 2019 This trial has been completed in Sweden (end date - 2018-12-28).